Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Depreciation & Amortization (CF) (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Depreciation & Amortization (CF) for 3 consecutive years, with $59000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 15.69% to $59000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $220000.0 through Dec 2025, up 94.69% year-over-year, with the annual reading at $220000.0 for FY2025, 94.69% up from the prior year.
  • Depreciation & Amortization (CF) hit $59000.0 in Q4 2025 for NewAmsterdam Pharma, down from $64000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $64000.0 in Q3 2025 to a low of $9000.0 in Q1 2023.
  • Historically, Depreciation & Amortization (CF) has averaged $31833.3 across 3 years, with a median of $23500.0 in 2024.
  • Biggest five-year swings in Depreciation & Amortization (CF): soared 292.31% in 2024 and later increased 15.69% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $13000.0 in 2023, then skyrocketed by 292.31% to $51000.0 in 2024, then rose by 15.69% to $59000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for NAMS at $59000.0 in Q4 2025, $64000.0 in Q3 2025, and $45000.0 in Q2 2025.